Related Experiment Video

Updated: Aug 19, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine

Roald Ravatn1, Valerie Wells, Leigh Nelson

  • 1Department of Chemical Biology, Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey 08854, USA.

Cancer Research
|March 9, 2005
PubMed

Insights

Beta-galactoside binding protein (betaGBP) effectively treats drug-resistant cancer cells by inducing apoptosis. This cytokine shows promise as an alternative cancer therapy for patients unresponsive to conventional treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells often develop resistance to chemotherapy through various mechanisms.
  • Drug resistance limits treatment options for many cancer patients.
  • Beta-galactoside binding protein (betaGBP) is an antiproliferative cytokine with potential anti-cancer properties.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of beta-galactoside binding protein (betaGBP) against cancer cells exhibiting diverse drug resistance mechanisms.
  • To investigate the mechanism by which betaGBP induces cancer cell death.

Main Methods:

  • Treatment of drug-resistant and parental cancer cell lines with betaGBP.
  • Analysis of drug resistance mechanisms including P-glycoprotein overexpression, DNA repair efficiency, and topoisomerase I/II alterations.
  • Cell cycle analysis to determine the effect of betaGBP on cell cycle progression.

Main Results:

  • Beta-galactoside binding protein (betaGBP) demonstrated equal therapeutic efficacy against drug-resistant and parental cancer cells.
  • Drug resistance mechanisms studied included P-glycoprotein overexpression, enhanced DNA repair, and topoisomerase mutations.
  • BetaGBP induced cell cycle arrest in the S phase, preceding apoptosis.

Conclusions:

  • Beta-galactoside binding protein (betaGBP) is effective against a range of drug-resistant cancer cells.
  • BetaGBP offers a potential new therapeutic strategy for refractory cancers.
  • The similar response profile suggests betaGBP's broad applicability in cancer treatment.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...